May 2013, Vol 2, No 3

Personalized Medicine in Oncology: Providing Insights to Optimally Utilize Personalized Medicine Concepts

Dear Colleague, I want to welcome you to this issue of Personalized Medicine in Oncology (PMO) with a few facts concerning personalized medicine (PM): 79% of late-stage oncology pipeline are targeted therapies Molecular profiling is driving many new targeted cancer therapeutics, with over 500 compounds coming soon, and 140 targets [ Read More ]

Greg Kalemkerian, MD


NCCN Updates Its Clinical Practice Guidelines

Updates to the Clinical Practice Guidelines of the National Comprehensive Cancer Network (NCCN) were presented at the NCCN 18th Annual Conference held in Hollywood, FL, March 13-17, 2013. For most tumor sites, the updates were few and minor, but the NCCN did introduce inaugural guidelines for survivorship. New Guidelines for [ Read More ]

Audrey Andrews


The Changing Oncology Landscape: Evolution or Revolution?

Panelists at the 18th Annual Conference of the National Comprehensive Cancer Network view the oncology world as rapidly changing, and the impact of this – for better or for worse – will be felt by healthcare providers, payers, and patients alike. “Certainly, this landscape is shifting beneath our feet,” said [ Read More ]

Audrey Andrews


Highlights From the American Association for Cancer Research Annual Meeting

The American Association for Cancer Research (AACR) 2013 Annual Meeting was held in Washington, DC, April 6-10, 2013. Following are selected highlights of early studies presented at the meeting. The hope is that these encouraging preliminary findings will be confirmed by larger studies and lead to advances in cancer care. [ Read More ]

Alice Goodman


Higher HER2 Expression Leads to Better Outcomes With T-DM1 in HER2-Positive Metastatic Breast Cancer

Among women with HER2-positive metastatic breast cancer, those with the highest expression of HER2 had the best outcomes on treatment with T-DM1, according to a biomarker analysis of the phase 3 EMILIA trial presented at the American Association for Cancer Research 2013 Annual Meeting. Further, the analysis found that T-DM1 [ Read More ]

Phoebe Starr


Personalizing Cancer Care, Policy, and the Payer Perspective:

An Interview with Peter F. Hayes of Healthcare Solutions

The Association for Value-Based Cancer Care (AVBCC) held its annual conference on May 2-5, 2013, in Hollywood, Florida. AVBCC is the fastest growing national specialty organization dedicated to improving the care of cancer patients and their quality of life by discussing, considering, and evaluating the value equation as it relates [ Read More ]

Peter F. Hayes

Interview with the Innovators

Sequential Therapy for Renal Cell Carcinoma

With several agents now approved and broadly available for the treatment of patients with advanced renal cell carcinoma (RCC), a great deal of attention has been focused on determining the most appropriate sequence of therapies. The concept of sequential therapy has developed for several reasons, including: 1) The availability of [ Read More ]

Daniel C. Cho, MD


Current Treatment of Myelofibrosis: How Far We Have Come and How Far We Have Yet to Go

At the 2012 conference of the Global Biomarkers Consortium, which took place March 9-11, 2012, in Orlando, Florida, Charles Schiffer, MD, from the Barbara Ann Karmanos Cancer Institute and Wayne State University in Detroit, Michigan, discussed the management of myeloproliferative neoplasms. Major advances in understanding the biology of hematologic malignancies, [ Read More ]


The MHealth Factor: A Bioinformatics Platform for Arming the Oncology Personalized Medicine Revolution

Personalized medicine (PM) applied to cancer diagnosis and treatment is really all about information: discovering it, synthesizing it, analyzing it, translating it to cancer pathophysiology, and finally sharing it with those who need to know what is going on inside the tumors. The rise of PM skill sets, as I [ Read More ]

Robert E. Henry

The Last Word

Crizotinib and Colorectal Cancer – A Couple to Be Tested?

Dr Stintzing is currently a postdoctoral fellow of the German Cancer Aid at the University of Southern California/Norris Comprehensive Cancer Center. Dr Stintzing’s research focus is on predictive and prognostic factors in the treatment of metastatic colorectal cancer. Dr Lenz is the Associate Director for Clinical Research and Co-Leader of [ Read More ]

Sebastian Stintzing, MD